199 related articles for article (PubMed ID: 7973776)
1. Protection of normal tissues from the cytotoxic effects of chemotherapy by amifostine (Ethyol): clinical experiences.
Capizzi RL
Semin Oncol; 1994 Oct; 21(5 Suppl 11):8-15. PubMed ID: 7973776
[TBL] [Abstract][Full Text] [Related]
2. Radiotherapeutic studies with amifostine (Ethyol).
Wasserman TH
Semin Oncol; 1994 Oct; 21(5 Suppl 11):21-5. PubMed ID: 7973775
[TBL] [Abstract][Full Text] [Related]
3. Amifostine reduces the incidence of cumulative nephrotoxicity from cisplatin: laboratory and clinical aspects.
Capizzi RL
Semin Oncol; 1999 Apr; 26(2 Suppl 7):72-81. PubMed ID: 10348264
[TBL] [Abstract][Full Text] [Related]
4. Neurologic protection by amifostine.
DiPaola RS; Schuchter L
Semin Oncol; 1999 Apr; 26(2 Suppl 7):82-8. PubMed ID: 10348265
[TBL] [Abstract][Full Text] [Related]
5. Future development of amifostine as a radioprotectant.
Werner-Wasik M
Semin Oncol; 1999 Apr; 26(2 Suppl 7):129-34. PubMed ID: 10348272
[TBL] [Abstract][Full Text] [Related]
6. Protection of normal tissues from the cytotoxic effects of radiation therapy: focus on amifostine.
Mehta MP
Semin Radiat Oncol; 1998 Oct; 8(4 Suppl 1):14-6. PubMed ID: 9794996
[TBL] [Abstract][Full Text] [Related]
7. Administration of the cytoprotectant amifostine.
Lindemann K
Clin J Oncol Nurs; 1998 Jul; 2(3):101-4. PubMed ID: 10232150
[TBL] [Abstract][Full Text] [Related]
8. Amifostine and combined-modality therapeutic approaches.
Mehta MP
Semin Oncol; 1999 Apr; 26(2 Suppl 7):95-101. PubMed ID: 10348267
[TBL] [Abstract][Full Text] [Related]
9. Chemoprotective and radioprotective effects of amifostine: an update of clinical trials.
Capizzi RL; Oster W
Int J Hematol; 2000 Dec; 72(4):425-35. PubMed ID: 11197208
[TBL] [Abstract][Full Text] [Related]
10. Protection of normal tissues from the cytotoxic effects of chemotherapy and radiation by amifostine (Ethyol): preclinical aspects.
van der Vijgh WJ; Peters GJ
Semin Oncol; 1994 Oct; 21(5 Suppl 11):2-7. PubMed ID: 7973774
[TBL] [Abstract][Full Text] [Related]
11. Radioprotective effects of amifostine.
Wasserman T
Semin Oncol; 1999 Apr; 26(2 Suppl 7):89-94. PubMed ID: 10348266
[TBL] [Abstract][Full Text] [Related]
12. The potential of amifostine: from cytoprotectant to therapeutic agent.
Santini V; Giles FJ
Haematologica; 1999 Nov; 84(11):1035-42. PubMed ID: 10553165
[TBL] [Abstract][Full Text] [Related]
13. Future development of amifostine in cancer treatment.
Alberts DS; Bleyer WA
Semin Oncol; 1996 Aug; 23(4 Suppl 8):90-9. PubMed ID: 8783674
[TBL] [Abstract][Full Text] [Related]
14. Carboplatin and paclitaxel in non-small cell lung cancer: the role of amifostine.
Selvaggi G; Belani CP
Semin Oncol; 1999 Apr; 26(2 Suppl 7):51-60. PubMed ID: 10348261
[TBL] [Abstract][Full Text] [Related]
15. Protection of normal tissue from the cytotoxic effects of chemotherapy and radiation by amifostine: clinical experiences.
Capizzi RL; Oster W
Eur J Cancer; 1995; 31A Suppl 1():S8-13. PubMed ID: 7577096
[TBL] [Abstract][Full Text] [Related]
16. Protection by amifostine of cyclophosphamide-induced myelosuppression.
Alberts DS
Semin Oncol; 1999 Apr; 26(2 Suppl 7):37-40. PubMed ID: 10348259
[TBL] [Abstract][Full Text] [Related]
17. Amifostine-mediated protection of normal bone marrow from cytotoxic chemotherapy.
Capizzi RL; Scheffler BJ; Schein PS
Cancer; 1993 Dec; 72(11 Suppl):3495-501. PubMed ID: 8242582
[TBL] [Abstract][Full Text] [Related]
18. Future directions in non-small cell lung cancer.
Schiller JH
Semin Oncol; 1999 Apr; 26(2 Suppl 7):120-4. PubMed ID: 10348270
[TBL] [Abstract][Full Text] [Related]
19. Pharmacoeconomics of amifostine in ovarian cancer.
Calhoun EA; Bennett CL
Semin Oncol; 1999 Apr; 26(2 Suppl 7):102-7. PubMed ID: 10348268
[TBL] [Abstract][Full Text] [Related]
20. [Clinical use of Amifostine (WR-2721) as a preparation protecting healthy tissues from the cytotoxic effects of chemotherapy and radiation therapy].
Wrembel-Wargocka J; Jabłońska H; Chomiczewski K
Przegl Lek; 1996; 53(11):820-5. PubMed ID: 9173447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]